Qiagen's Coup in DNA Sample Prep
Executive Summary
Qiagen's success in exploiting an overlooked niche in research diagnostics--sample prep for nucleic acid tests--has driven an extraordinary growth story. But its performance has attracted the attention of big diagnostics companies. As it looks to expand into clinical markets, it faces levels of competition it's never seen before.
You may also be interested in...
Qiagen Buys Molecular Staging: Stalking PCR
Although scientific and clinical interest in molecular diagnostics is at an all-time high, companies are still struggling to find the right business model for the field. Qiagen's recent acquisition of the assets of Molecular Staging, one of the sector's pioneers, reflects the promise and limitations of a field in which competition is fierce, development time is lengthy, and technology is evolving much faster than general market acceptance.
Beckman Coulter's Play for High Growth
With the Coulter integration successful, Beckman Coulter looks for high-growth opportunities outside of its traditional businesses. Beckman, through internal efforts in its life sciences business and a series of small alliances, is making a play in genomics and proteomics. In addition to building up near-term revenues, the aim is to find new "content" in the form of assays for its clinical business.
GSK Makes New Adult Immunization Push, Seeks Reimbursement Changes Following RSV Approvals
From ACIP to Part D to data transparency, GSK has several policy asks as it prepares to launch its new RSV vaccine for older adults. The Pink Sheet spoke with GSK’s vaccine policy lead about the firm’s new data platform and the worrisome US vaccination trends following the Covid pandemic.